Ciprofloxacin: single versus multiple doses in transrectal ultrasound guided prostate biopsy
Muhammad Rafiq1, Fawzy Farag1,2, Kate Manley1
1Department of Urology, Norfolk & Norwich University Hospital, Norwich, United Kingdom.
Introduction:
There is rising concern regarding overuse of fluoroquinolones due to severe musculoskeletal and neurological side effects, and development of resistant microorganisms. In June 2019, the European Commission recommended fluoroquinolones should not be used routinely for prophylaxis in urological surgical procedures. Methods to reduce unnecessary exposure to fluroquinolones should be investigated.The aim of this article was to determine differences in hospital admission secondary to sepsis following transrectal ultrasound (TRUS) guided prostate biopsies between patients who received single vs. multiple doses of fluoroquinolones.
Material And Methods:
A retrospective analysis (June 2017-September 2018) of 200 consecutive TRUS biopsies at a single centre was undertaken. Group 1 (n = 100) received 750 mg ciprofloxacin 1-hr before their procedure followed by 3 days of ciprofloxacin 250 mg BD. Group 2 (n = 100) received a single dose of 750 mg ciprofloxacin 1-hr before the procedure. Midstream urine (MSU) culture results were examined pre-biopsy and 7 days post-biopsy. Data was also gathered on readmission rates to hospital as a result of urosepsis.
Results:
A total of 1% of patients in each group required hospital admission secondary to Escherichia coli sepsis. A further 4% (n = 4) in Group 1 developed a urinary tract infection requiring antibiotic treatment post biopsy compared with 1% (n = 1) in Group 2. There was no statistically significant difference in development of infectious complications post-biopsy between the two groups (p >0.05).
Conclusions:
A single prophylactic dose of 750 mg of ciprofloxacin 1-hour pre-biopsy is as effective as multiple doses for TRUS guided prostate biopsy. Avoiding an unnecessary and prolonged course of fluoroquinolones has advantages in reducing potential side effects and development of resistant pathogens.
Insights
A single dose of ciprofloxacin before prostate biopsy is as effective as multiple doses in preventing sepsis. This approach reduces fluoroquinolone exposure, minimizing side effects and antimicrobial resistance.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Background:
- Growing concerns exist regarding fluoroquinolone overuse, linked to severe side effects and antimicrobial resistance.
- European guidelines recommend against routine fluoroquinolone prophylaxis in urological procedures.
- Investigating methods to reduce unnecessary fluoroquinolone exposure is crucial.
Purpose of the Study:
- To compare hospital admissions for sepsis after transrectal ultrasound (TRUS)-guided prostate biopsies.
- To evaluate differences between single and multiple fluoroquinolone prophylactic doses.
Main Methods:
- Retrospective analysis of 200 TRUS-guided prostate biopsies (June 2017-September 2018).
- Group 1 (n=100): Single 750 mg ciprofloxacin dose pre-biopsy + 3 days of 250 mg ciprofloxacin BD.
- Group 2 (n=100): Single 750 mg ciprofloxacin dose pre-biopsy.
- Analysis included pre- and post-biopsy urine cultures and hospital readmission rates for urosepsis.
Main Results:
- 1% of patients in each group were admitted for Escherichia coli sepsis.
- Urinary tract infections requiring antibiotics occurred in 4% of Group 1 versus 1% in Group 2.
- No statistically significant difference in infectious complications between the groups (p >0.05).
Conclusions:
- A single prophylactic dose of ciprofloxacin is as effective as multiple doses for TRUS-guided prostate biopsies.
- Avoiding prolonged fluoroquinolone courses reduces potential side effects.
- This strategy aids in combating the development of resistant pathogens.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Imaging Studies III: Computed Tomography
Imaging Studies II: Ultrasonography
Urologic Endoscopic Procedure: Cystoscopic Examination
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence


